Fluorouracil-based combinations in the treatment of metastatic breast cancer.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 9516601
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chemotherapy for advanced disease. How to raise enthusiasm.

  1996cited by this paper
• Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer.

  1996cited by this paper
• Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro.

  1995cited by this paper
• Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.

  1995cited by this paper
• Newest clinical approaches with paclitaxel (Taxol): Introduction

  1994cited by this paper
• Randomized Trial of Two Doses of Taxol in Metastatic Breast Cancer: An Interim Analysis

  1994cited by this paper
• Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines.

  1994cited by this paper
• Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.

  1993cited by this paper
• Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules.

  1992cited by this paper
• Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.

  1992cited by this paper
• Taxol: the first of the taxanes, an important new class of antitumor agents.

  1992cited by this paper
• Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

  1991cited by this paper
• Taxol: twenty years later, the story unfolds.

  1991cited by this paper
• Taxol: a novel investigational antimicrotubule agent.

  1990cited by this paper
• 5‐fluorouracil rechallenge by protracted infusion in refractory breast cancer

  1989influential reference
• 5‐fluorouracil with leucovorin in breast cancer

  1989cited by this paper
• Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium.

  1989cited by this paper
• Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer.

  1989influential reference
• Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.

  1988cited by this paper
• Cisplatin as first-line therapy for metastatic breast cancer.

  1988cited by this paper
• A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.

  1987cited by this paper
• Continuous 5-fluorouracil infusion in refractory carcinoma of the breast

  1987cited by this paper
• 5-Fluorouracil and high-dose folinic acid as salvage treatment of advanced breast cancer: an update.

  1987cited by this paper
• Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.

  1987cited by this paper
• Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.

  1986cited by this paper
• Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells.

  1986cited by this paper
• Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil.

  1983cited by this paper
• The effect of derivatives of folic acid on the fluorodeoxyuridylate-thymidylate synthetase covalent complex in human colon xenografts.

  1982cited by this paper
• Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil.

  1981cited by this paper
• Nonlinear pharmacokinetic models for 5‐fluorouracil in man: Intravenous and intraperitoneal routes

  1980cited by this paper
• A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil.

  1978cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Drug Repurposing and Molecular Insights in the Fight Against Breast Cancer

  2024cites this paper
• RETRACTED ARTICLE: Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer

  2020cites this paper
• Methylglyoxal in combination with 5-Fluorouracil elicits improved chemosensitivity in breast cancer through apoptosis and cell cycle inhibition.

  2019cites this paper
• Drug repurposing for breast cancer therapy: Old weapon for new battle

  2019cites this paper
• Role of Nuclear Factor Erythroid 2-Related Factor 2 (NRF-2) Mediated Antioxidant Response on the Synergistic Antitumor Effect of L-Arginine and 5-Fluro Uracil (5FU) in Breast Adenocarcinoma.

  2019cites this paper
• Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer

  2008cites this paper
• Developments in chemotherapy of breast cancer

  2000cites this paper
• Recent developments in breast cancer therapy.

  1999cites this paper
• Paclitaxel plus nonanthracycline combinations in metastatic breast cancer.

  1999cites this paper
• Optimizing Chemotherapy for Patients with Advanced Breast Cancer

  1999cites this paper
• Schedule dependency of 5-fluorouracil.

  1999cites this paper
• Cytostatic therapy for metastasized mammary carcinoma – New substances and innovative combinations

  1999cites this paper